https://drug-dev.com/bora-appoints-first-division-president-of-its-cdmo-business/ 2024-10-03T13:55:11+00:00 https://drug-dev.com/wp-content/uploads/2024/10/JD-Mowery.jpg https://drug-dev.com/first-patient-dosed-in-phase-2-trial-of-tlx250-cdx-for-detection-of-recurrent-kidney-cancer-after-surgery/ 2024-10-03T14:01:05+00:00 https://drug-dev.com/hovione-zerion-pharma-create-joint-venture-to-further-expand-use-of-dispersome-technology/ 2024-10-03T14:07:49+00:00 https://drug-dev.com/legend-biotech-to-establish-new-state-of-the-art-cell-therapy-rd-facility-in-philadelphia/ 2024-10-03T14:13:29+00:00 https://drug-dev.com/bioduro-sundia-launches-new-compound-management-center-strengthening-drug-discovery-services/ 2024-10-03T14:18:20+00:00 https://drug-dev.com/wp-content/uploads/2024/10/BioDuro-Sundia-Compound-Management-Center.jpg https://drug-dev.com/recipharm-strengthens-pharmaceutical-development-capabilities-with-strategic-investments/ 2024-10-03T14:27:46+00:00 https://drug-dev.com/stevanato-group-introduces-the-new-vertiva-10ml-expanding-treatment-options-with-innovation/ 2024-10-03T15:24:12+00:00 https://drug-dev.com/wp-content/uploads/2024/10/Picture2-3.png https://drug-dev.com/sterling-pharma-solutions-announces-partnership-with-soligenix/ 2024-10-03T18:18:46+00:00 https://drug-dev.com/biodexa-provides-update-on-progression-free-overall-survival-in-phase-1-study-of-mtx110-in-recurrent-glioblastoma/ 2024-10-04T13:08:06+00:00 https://drug-dev.com/abivax-announces-first-patient-enrolled-in-phase-2b-trial-of-obefazimod-in-crohns-disease/ 2024-10-04T13:12:25+00:00 https://drug-dev.com/monopar-initiates-clinical-trial-of-novel-upar-targeted-radiopharmaceutical-therapy-in-advanced-cancers/ 2024-10-07T13:12:05+00:00 https://drug-dev.com/akoyas-leading-spatial-proteomics-platforms-selected-for-use-by-ground-breaking-uk-based-manifest-consortium-to-revolutionize-cancer-immunotherapy/ 2024-10-07T13:15:03+00:00 https://drug-dev.com/cybrexa-therapeutics-announces-first-patient-dosed-with-first-in-class-peptide-drug-conjugate-in-phase-2-trial-in-ovarian-cancer/ 2024-10-07T13:20:56+00:00 https://drug-dev.com/sgs-announces-expansion-of-biopharmaceutical-testing-capabilities/ 2024-10-07T13:23:28+00:00 https://drug-dev.com/microbiotica-announces-first-patient-dosed-in-its-international-phase-1b-trial-melody-1-of-mb097-precision-microbiome-co-therapy-in-advanced-melanoma/ 2024-10-07T13:26:48+00:00 https://drug-dev.com/actylis-acquires-pharm-rx-a-leading-value-added-supplier-of-specialty-ingredients-for-the-vitamin-mineral-supplement-pharmaceutical-industries/ 2024-10-07T13:29:23+00:00 https://drug-dev.com/avillion-announces-positive-high-level-results-from-phase-3-batura-trial-with-astrazenecas-inhaled-anti-inflammatory-medication-airsupra-in-asthma-patients/ 2024-10-07T13:36:52+00:00 https://drug-dev.com/bd-ten23-health-partner-to-advance-efficiency-quality-in-aseptic-manufacturing-with-rfid-enabled-prefillable-syringes/ 2024-10-07T13:42:02+00:00 https://drug-dev.com/neonc-technologies-receives-pharma-tech-outlooks-top-drug-delivery-platform-award-for-2024/ 2024-10-07T15:06:00+00:00 https://drug-dev.com/veranova-expands-advisory-board-with-distinguished-industry-leaders/ 2024-10-07T16:41:28+00:00 https://drug-dev.com/wp-content/uploads/2024/10/Picture1-1.jpg https://drug-dev.com/wp-content/uploads/2024/10/Picture2.jpg https://drug-dev.com/datwyler-launches-neoflex-plungers-for-large-volume-biologics-in-auto-wearable-injectors/ 2024-10-08T14:25:39+00:00 https://drug-dev.com/wp-content/uploads/2024/10/1.png https://drug-dev.com/grin-therapeutics-announces-initiation-of-astroscape-clinical-trial-of-radiprodil-for-treatment-of-tuberous-sclerosis-complex-focal-cortical-dysplasia-type-ii/ 2024-10-08T14:34:29+00:00 https://drug-dev.com/immunesensor-therapeutics-initiates-dosing-in-phase-1-trial-of-lead-cgas-inhibitor-drug-candidate/ 2024-10-08T14:37:32+00:00 https://drug-dev.com/traws-pharma-announces-positive-topline-phase-1-data-for-flu-candidate/ 2024-10-08T14:41:15+00:00 https://drug-dev.com/mink-therapeutics-autonomous-therapeutics-announce-collaboration-to-develop-novel-therapies-targeting-metastatic-tumors/ 2024-10-08T14:43:35+00:00 https://drug-dev.com/kindeva-drug-delivery-completes-registration-batch-at-state-of-the-art-aseptic-injectable-fill-finish-facility/ 2024-10-08T14:46:00+00:00 https://drug-dev.com/avalo-announces-first-patient-dosed-in-phase-2-trial-of-avtx-009-for-the-treatment-of-hidradenitis-suppurativa/ 2024-10-08T14:48:38+00:00 https://drug-dev.com/mestag-therapeutics-announces-license-research-collaboration-with-msd/ 2024-10-08T14:50:57+00:00 https://drug-dev.com/simtra-biopharma-solutions-expands-capabilities-with-14m-investment-in-adc-conjugation-purification-clinical-suite/ 2024-10-08T14:54:04+00:00 https://drug-dev.com/qinotto-lilly-enter-research-collaboration-license-agreement/ 2024-10-08T16:11:22+00:00 https://drug-dev.com/hbc-immunology-completes-in-vivo-drug-lead-studies-for-prostrate-cancer-treatment/ 2024-10-09T13:22:29+00:00 https://drug-dev.com/syneos-health-appoints-costa-panagos-as-chief-executive-officer/ 2024-10-09T13:27:56+00:00 https://drug-dev.com/wp-content/uploads/2024/10/1728478285188.jpg https://drug-dev.com/sonnet-biotherapeutics-enters-licensing-agreement-with-alkem-laboratories/ 2024-10-09T13:31:52+00:00 https://drug-dev.com/braindos-formulated-dual-gip-glp-1-receptor-agonist-tirzepatide-outperforms-tirzepatide-solution-in-preclinical-study/ 2024-10-09T13:42:04+00:00 https://drug-dev.com/wp-content/uploads/2024/10/Picture1.png https://drug-dev.com/panavance-therapeutics-provides-update-on-phase-1-clinical-trial-of-misetionamide-in-pancreatic-cancer/ 2024-10-09T13:51:24+00:00 https://drug-dev.com/fda-grants-orphan-drug-designation-to-can-fites-namodenoson-for-pancreatic-cancer/ 2024-10-09T13:55:37+00:00 https://drug-dev.com/palisade-bio-cleared-to-commence-phase-1-clinical-study-for-ulcerative-colitis-treatment/ 2024-10-10T13:21:42+00:00 https://drug-dev.com/achieve-life-sciences-announces-completion-of-enrollment-in-clinical-trial-successful-outcome-of-the-first-data-safety-monitoring-committee-meeting/ 2024-10-10T13:25:37+00:00 https://drug-dev.com/nanoscope-announces-plans-to-submit-bla-for-retinitis-pigmentosa-treatment/ 2024-10-10T13:33:45+00:00 https://drug-dev.com/transcode-therapeutics-completes-initial-dosing-of-first-cohort-in-phase-1-trial-with-a-microrna-targeted-technology/ 2024-10-10T13:37:32+00:00 https://drug-dev.com/mitorx-therapeutics-announces-publication-showing-mitochondrial-sulfide-donor-ap39-significantly-alleviates-obesity/ 2024-10-10T13:41:40+00:00 https://drug-dev.com/honeywell-technology-to-power-devpro-biopharmas-next-generation-low-emission-respiratory-inhaler/ 2024-10-10T15:35:31+00:00 https://drug-dev.com/ardena-signs-agreement-to-expand-us-footprint-with-acquisition-of-advanced-drug-product-manufacturing-facility/ 2024-10-14T13:20:58+00:00 https://drug-dev.com/inventiva-announces-financing-to-advance-nativ3-phase-3-mash-study/ 2024-10-14T13:30:36+00:00 https://drug-dev.com/transgene-provides-update-on-phase-2-trial-of-therapeutic-cancer-vaccine-in-recurrent-or-metastatic-hpv16-positive-cervical-anogenital-cancers/ 2024-10-14T13:34:58+00:00 https://drug-dev.com/novacina-expands-perth-facility-to-offer-clinical-supplies-service-for-global-market/ 2024-10-14T13:45:46+00:00 https://drug-dev.com/sapio-sciences-enhances-bioanalysis-lims-eln-with-advanced-immunogenicity-capabilities/ 2024-10-15T13:22:58+00:00 https://drug-dev.com/fda-clears-annovis-to-launch-pivotal-phase-3-alzheimers-studies-paving-the-way-to-ndas/ 2024-10-15T13:27:33+00:00 https://drug-dev.com/akari-therapeutics-announces-effectiveness-of-form-s-4-general-meeting-date-of-november-7-2024-related-to-peak-bio-merger/ 2024-10-15T13:31:18+00:00 https://drug-dev.com/indaptus-therapeutics-initiates-unrestricted-enrollment-of-patients-on-decoy20-weekly-dosing-based-on-encouraging-safety-data/ 2024-10-15T13:33:32+00:00 https://drug-dev.com/immuneering-granted-orphan-drug-designation-for-pancreatic-cancer-treatment/ 2024-10-15T13:35:19+00:00 https://drug-dev.com/ocular-therapeutix-announces-accelerated-timelines-for-sol-1-registrational-trial-of-axpaxli-in-wet-amd/ 2024-10-15T13:38:46+00:00 https://drug-dev.com/lgm-pharma-expands-analytical-testing-services-with-new-endotoxin-rapid-sterility-testing-capabilities/ 2024-10-15T13:41:18+00:00 https://drug-dev.com/molecure-ocean-biomedical-sign-exclusive-licensing-agreement-for-development-commercialization-of-selective-ykl-40-inhibitors/ 2024-10-15T13:44:59+00:00 https://drug-dev.com/impact-biomedical-inc-announces-issuance-of-patent-for-linebacker-technology-targeting-inflammatory-disease/ 2024-10-15T13:53:38+00:00 https://drug-dev.com/bespak-ht-presspart-announce-availability-of-gmp-pilot-line-for-low-gwp-pmdis/ 2024-10-15T13:58:17+00:00 https://drug-dev.com/lipella-pharmaceuticals-announces-patent-allowance-for-innovative-liposomal-drug-delivery-platform/ 2024-10-15T14:01:55+00:00 https://drug-dev.com/lonza-completes-expansion-of-new-drug-product-services-facility-in-basel-ch/ 2024-10-15T14:56:32+00:00 https://drug-dev.com/productlife-group-acquires-halloran-to-further-expand-its-global-reach-capabilities-to-support-development-of-new-therapies/ 2024-10-16T13:30:01+00:00 https://drug-dev.com/gri-bio-presents-positive-preclinical-data-demonstrating-gri-0621s-ability-to-inhibit-invariant-natural-killer-t-cell-activity-reduce-important-inflammatory-fibrotic-drivers-in-idiopathic/ 2024-10-16T13:32:54+00:00 https://drug-dev.com/cellular-origins-fresenius-kabi-sign-development-agreement-for-scalable-automation-of-cell-gene-therapy-manufacturing/ 2024-10-16T13:37:08+00:00 https://drug-dev.com/wave-life-sciences-announces-first-ever-therapeutic-rna-editing-in-humans-achieved-in-restoraation-2-trial-of-wve-006-in-alpha-1-antitrypsin-deficiency/ 2024-10-16T13:38:43+00:00 https://drug-dev.com/iggenix-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-ignx001-in-peanut-allergy/ 2024-10-16T13:40:54+00:00 https://drug-dev.com/okyo-pharma-announces-start-of-phase-2-clinical-trial-to-treat-patients-with-neuropathic-corneal-pain/ 2024-10-16T13:46:46+00:00 https://drug-dev.com/cullinan-therapeutics-receives-ind-clearance-for-cln-978-administered-subcutaneously-in-patients-with-moderate-to-severe-systemic-lupus-erythematosus/ 2024-10-16T13:49:45+00:00 https://drug-dev.com/mrna-licensing-agreements-surge-800-in-value-as-confidence-grows-beyond-vaccines/ 2024-10-16T13:59:07+00:00 https://drug-dev.com/wp-content/uploads/2024/10/00.png https://drug-dev.com/biognosys-presents-major-innovations-across-the-spectrum-of-proteomics-research-applications/ 2024-10-17T13:20:29+00:00 https://drug-dev.com/bioaegis-therapeutics-enrolls-first-patient-in-phase-2-clinical-trial-of-immune-regulator-for-treatment-of-acute-respiratory-distress-syndrome/ 2024-10-17T13:23:07+00:00 https://drug-dev.com/immutep-announces-first-in-human-phase-1-study-of-imp761-progresses-to-dose-escalation-portion-of-trial/ 2024-10-17T13:24:38+00:00 https://drug-dev.com/avacta-expands-its-pipeline-with-two-novel-assets-developed-using-its-precision-platform/ 2024-10-17T13:30:07+00:00 https://drug-dev.com/novadip-reports-promising-interim-results-from-first-in-human-proof-of-concept-trial-of-new-game-changer-in-bone-field/ 2024-10-17T13:36:20+00:00 https://drug-dev.com/birchbiomed-receives-health-canada-green-light-to-start-the-last-stage-of-its-groundbreaking-clinical-program-to-minimize-scarring-from-burns/ 2024-10-24T13:28:08+00:00 https://drug-dev.com/gri-bio-raises-13-9-million-in-gross-proceeds-since-the-beginning-of-2024/ 2024-10-24T13:31:52+00:00 https://drug-dev.com/upm-biomedicals-launches-fibgel-worlds-first-injectable-nanocellulose-hydrogel-for-medical-devices/ 2024-10-24T13:36:09+00:00 https://drug-dev.com/rhythm-pharmaceuticals-axovia-therapeutics-announce-joint-research-collaboration-in-bardet-biedl-syndrome/ 2024-10-24T13:41:13+00:00 https://drug-dev.com/rentschler-biopharma-announces-largest-single-investment-at-its-headquarters-in-germany/ 2024-10-24T13:44:16+00:00 https://drug-dev.com/poltreg-launches-phase-2-cell-therapy-trial-in-children-with-presymptomatic-diabetes/ 2024-10-24T13:46:58+00:00 https://drug-dev.com/bd-ypsomed-collaborate-to-advance-self-injection-systems-for-high-viscosity-biologics/ 2024-10-24T13:52:40+00:00 https://drug-dev.com/lonza-extends-collaboration-with-major-pharmaceutical-partner-for-integrated-commercial-supply-of-antibody-drug-conjugates/ 2024-10-24T13:57:42+00:00 https://drug-dev.com/aptar-awarded-federal-government-contract-to-advance-novel-sterilization-technology-for-medical-devices/ 2024-10-24T14:03:08+00:00 https://drug-dev.com/wp-content/uploads/2024/10/Picture1-1.png https://drug-dev.com/nimbus-therapeutics-presents-first-preclinical-data-on-novel-wrn-inhibitor/ 2024-10-24T14:06:24+00:00 https://drug-dev.com/interius-biotherapeutics-doses-first-patient-with-in-vivo-chimeric-antigen-receptor-gene-therapy-for-b-cell-malignancies/ 2024-10-24T14:09:39+00:00 https://drug-dev.com/ocuphire-pharma-announces-acquisition-of-opus-genetics/ 2024-10-24T14:12:21+00:00 https://drug-dev.com/purple-biotech-presents-new-data-for-its-novel-tri-specific-t-cell-nk-cell-engagers-antibody-platform/ 2024-10-25T13:33:38+00:00 https://drug-dev.com/catalent-boston-adds-to-oral-spray-drying-capacity-capabilities-to-support-late-stage-clinical-trials-commercialization/ 2024-10-28T13:47:34+00:00 https://drug-dev.com/first-ever-long-acting-injectable-for-malaria-prevention-administered-to-study-volunteers/ 2024-10-28T13:51:33+00:00 https://drug-dev.com/lisata-therapeutics-announces-sponsored-preclinical-research-agreement-with-university-of-cincinnati-to-study-for-endometriosis-treatment/ 2024-10-28T13:57:10+00:00 https://drug-dev.com/pluri-collaborates-with-bar-ilan-university-to-advance-cancer-immunotherapy-for-solid-tumors/ 2024-10-28T14:00:21+00:00 https://drug-dev.com/biora-therapeutics-shares-progress-on-smaller-biojet-clinical-device-with-largest-payload-of-any-ingestible-injectable/ 2024-10-28T14:03:50+00:00 https://drug-dev.com/candel-therapeutics-showcases-innovative-cancer-therapy-candidates/ 2024-10-28T14:08:18+00:00 https://drug-dev.com/vianautis-bio-signs-strategic-collaboration-agreement-with-lilly-to-develop-novel-products-delivering-genetic-medicines/ 2024-10-28T14:12:25+00:00 https://drug-dev.com/cellevate-demonstrates-successful-scale-up-of-its-cellevat3d-nanofiber-microcarriers-for-biomanufacturing-at-testa-center/ 2024-10-28T14:22:06+00:00 https://drug-dev.com/monte-rosa-therapeutics-announces-global-license-agreement-with-novartis-to-advance-t-b-cell-modulating-vav1-directed-molecular-glue-degraders/ 2024-10-28T14:25:37+00:00 https://drug-dev.com/immunoprecise-advances-anti-aging-research-with-mayo-clinic-study-poised-to-tap-into-81-billion-market-with-ai-technology/ 2024-10-28T14:31:03+00:00 https://drug-dev.com/modifi-biosciences-acquired-by-merck/ 2024-10-28T14:45:00+00:00 https://drug-dev.com/shuttle-pharma-doses-first-patients-in-phase-2-trial-of-ropidoxuridine-for-treatment-of-patients-with-glioblastoma/ 2024-10-29T13:33:46+00:00 https://drug-dev.com/eledon-pharmaceuticals-announces-positive-initial-data-from-subjects-with-type-1-diabetes-treated-with-tegoprubart-as-part-of-an-immunosuppression-regimen-following-islet-transplantation/ 2024-10-29T13:38:12+00:00 https://drug-dev.com/ardena-expands-bioanalytical-services-in-europe/ 2024-10-29T13:42:24+00:00 https://drug-dev.com/sagimet-biosciences-announces-successful-completion-of-end-of-phase-2-interactions-with-fda-on-the-development-of-denifanstat-for-mash-phase-3-program-initiation-expected-by-end-of-2024/ 2024-10-29T13:44:54+00:00 https://drug-dev.com/valanx-biotech-fina-biosolutions-introduce-clickcrm-for-rapid-conjugate-vaccine-development/ 2024-10-29T13:48:42+00:00 https://drug-dev.com/naobios-sumagen-successfully-optimize-hiv-vaccine-candidate-for-industrial-production/ 2024-10-29T13:52:53+00:00 https://drug-dev.com/isomab-announces-strategic-collaboration-with-catalent/ 2024-10-29T15:02:39+00:00 https://drug-dev.com/tiziana-life-sciences-announces-positive-results-from-ozempic-nasal-anti-cd3-combination-study/ 2024-10-30T13:08:37+00:00 https://drug-dev.com/wp-content/uploads/2024/10/1-1.png https://drug-dev.com/enlivex-receives-notice-of-allowance-for-patent-application-covering-the-use-of-allocetra-in-patients-with-osteoarthritis/ 2024-10-30T13:12:30+00:00 https://drug-dev.com/numab-therapeutics-announces-initiation-of-phase-1-clinical-study-of-nm32-program-in-patients-with-solid-tumors/ 2024-10-30T13:16:06+00:00 https://drug-dev.com/marimed-commences-manufacturing-operations-in-missouri/ 2024-10-30T13:20:37+00:00 https://drug-dev.com/novartis-scemblix-fda-approved-in-newly-diagnosed-cml-offering-superior-efficacy-favorable-safety-tolerability-profile/ 2024-10-30T13:31:08+00:00 https://drug-dev.com/pci-pharma-services-wins-supply-chain-excellence-award-for-groundbreaking-digital-platform-to-manage-clinical-trials-commercial-lifespans/ 2024-10-30T14:28:01+00:00 https://drug-dev.com/wp-content/uploads/2024/10/000.png https://drug-dev.com/abzena-announces-major-expansion-in-microbiology-laboratory-space-in-support-of-biologic-manufacturing/ 2024-10-30T14:59:16+00:00 https://drug-dev.com/sterling-pharma-solutions-expands-gmp-adc-manufacturing-capacity-at-deeside-uk/ 2024-10-30T17:05:10+00:00 https://drug-dev.com/palisade-bio-announces-positive-data-from-two-ex-vivo-translational-studies-for-ulcerative-colitis-treatment/ 2024-10-31T13:14:57+00:00 https://drug-dev.com/evogene-announces-collaboration-with-google-cloud-to-pioneer-generative-ai-foundation-model-for-novel-small-molecule-design/ 2024-10-31T13:20:48+00:00 https://drug-dev.com/karyopharm-announces-favorable-change-in-co-primary-endpoint-for-pivotal-phase-3-sentry-trial-in-myelofibrosis/ 2024-10-31T13:26:14+00:00 https://drug-dev.com/curevo-presents-positive-shingles-vaccine-outcomes-data/ 2024-10-31T13:31:08+00:00 https://drug-dev.com/sgs-launches-new-consultancy-services-to-transform-accelerate-clinical-trial-submissions/ 2024-10-31T15:23:19+00:00 https://drug-dev.com/intensity-therapeutics-the-swiss-group-for-clinical-cancer-research-sakk-announce-first-patient-dosed-in-the-randomized-presurgical-triple-negative-breast-cancer-phase-2-clinical-trial/ 2024-10-31T15:38:10+00:00 https://drug-dev.com/quotient-sciences-medicines-for-malaria-venture-announce-dosing-of-first-ever-long-acting-injectable-for-malaria-prevention-to-study-volunteers/ 2024-10-31T20:04:01+00:00 https://drug-dev.com/abbvie-to-acquire-aliada-therapeutics-strengthening-focus-in-alzheimers-disease-neuroscience-pipeline/ 2024-11-01T13:39:12+00:00 https://drug-dev.com/sgs-announces-expansion-of-biopharmaceutical-testing-capabilities-2/ 2024-11-04T14:08:09+00:00 https://drug-dev.com/conduit-pharmaceuticals-announces-new-addition-to-its-autoimmune-pipeline/ 2024-11-04T14:12:50+00:00 https://drug-dev.com/can-fite-anti-obesity-drug-received-patent-allowance-in-australia/ 2024-11-04T14:16:09+00:00 https://drug-dev.com/ema-confirms-acceptance-of-marketing-authorization-application-for-a-proposed-biosimilar-to-simponi/ 2024-11-04T14:20:09+00:00 https://drug-dev.com/mannkind-successfully-completes-phase-1-trial-of-nintedanib-dpi-for-pulmonary-fibrotic-diseases/ 2024-11-04T14:22:54+00:00 https://drug-dev.com/nouscoms-off-the-shelf-neoantigen-immunotherapy-continues-to-elicit-potent-durable-immune-responses-in-lynch-syndrome-carriers-highlighting-its-potential-to-intercept-cancer/ 2024-11-05T14:25:23+00:00 https://drug-dev.com/prognomiq-announces-34-million-financing-to-advance-development-of-early-detection-test-for-lung-cancer-with-multi-omics-platform/ 2024-11-05T14:28:39+00:00 https://drug-dev.com/nxera-pharma-antiverse-enter-collaboration-to-design-novel-gpcr-targeted-antibody-therapeutics-using-generative-ai/ 2024-11-05T14:37:01+00:00 https://drug-dev.com/transgene-probiogen-join-forces-to-advance-individualized-cancer-vaccine-development/ 2024-11-05T14:39:20+00:00 https://drug-dev.com/rice-bioengineers-shed-light-on-dosing-challenges-for-cancer-immunotherapy/ 2024-11-06T14:09:59+00:00 https://drug-dev.com/sgs-expands-cutting-edge-spray-drug-delivery-testing-capabilities-in-belgium-health-science-laboratory/ 2024-11-06T14:24:29+00:00 https://drug-dev.com/lisata-therapeutics-valo-therapeutics-announce-preclinical-research-collaboration/ 2024-11-06T14:29:25+00:00 https://drug-dev.com/bespak-orbia-fluor-energy-materials-unite-to-accelerate-transition-to-climate-friendly-inhalers/ 2024-11-06T14:33:26+00:00 https://drug-dev.com/sonnet-biotherapeutics-announces-patent-covering-a-variant-il-18-incorporated-into-two-novel-immunotherapeutic-candidates/ 2024-11-06T16:09:18+00:00 https://drug-dev.com/palvella-therapeutics-announces-first-patient-dosed-in-phase-3-clinical-trial-for-microcystic-lymphatic-malformations-treatment/ 2024-11-07T14:32:20+00:00 https://drug-dev.com/palisade-bio-announces-first-subject-dosed-in-phase-1-study-for-moderate-to-severe-ulcerative-colitis-treatment/ 2024-11-07T14:37:30+00:00 https://drug-dev.com/tilray-medical-announces-positive-results-from-study-on-oral-cannabis-extract-for-chemotherapy-induced-emesis/ 2024-11-07T14:43:55+00:00 https://drug-dev.com/adipo-therapeutics-presents-positive-study-results-about-potential-obesity-treatment/ 2024-11-07T15:44:29+00:00 https://drug-dev.com/lonzas-synaffix-collaborates-with-bighat-biosciences-on-the-development-of-a-machine-learning-designed-adc/ 2024-11-07T17:30:43+00:00 https://drug-dev.com/transgene-nec-present-new-data-confirming-clinical-proof-of-principle-for-neoantigen-cancer-vaccine-in-head-neck-cancer/ 2024-11-08T14:51:25+00:00 https://drug-dev.com/cero-therapeutics-presents-preclinical-data-demonstrating-cer-1236-killing-ovarian-cancer-cell-lines-without-toxicity/ 2024-11-11T14:27:14+00:00 https://drug-dev.com/can-fite-achieves-milestone-with-first-patient-dosing-in-pancreatic-cancer-phase-2a-clinical-trial/ 2024-11-11T14:31:26+00:00 https://drug-dev.com/indaptus-therapeutics-pioneering-research-on-novel-immunotherapy-approach-published-in-peer-reviewed-frontiers-in-immunology/ 2024-11-11T15:57:57+00:00 https://drug-dev.com/brainstorm-cell-therapeutics-pluri-partner-to-support-nurown-phase-3b-trial-manufacturing/ 2024-11-11T16:42:05+00:00 https://drug-dev.com/gelteq-expands-operations-in-united-states/ 2024-11-12T14:36:28+00:00 https://drug-dev.com/lonza-to-expand-bioconjugation-in-visp-ch-with-two-additional-manufacturing-suites/ 2024-11-12T14:39:19+00:00 https://drug-dev.com/enlivex-announces-enrollment-dosing-of-the-first-10-patients-in-the-randomized-phase-2-stage-of-its-allocetra-trial/ 2024-11-12T14:43:11+00:00 https://drug-dev.com/araris-biotech-publishes-foundational-science-behind-its-novel-antibody-drug-conjugate-platform/ 2024-11-12T14:46:13+00:00 https://drug-dev.com/zenas-biopharma-completes-targeted-enrollment-of-the-phase-3-indigo-trial-of-obexelimab-in-immunoglobulin-g4-related-disease/ 2024-11-12T14:53:50+00:00 https://drug-dev.com/attralus-therapeutic-at-02-receives-orphan-drug-designation-for-the-treatment-of-attr-amyloidosis/ 2024-11-12T14:57:39+00:00 https://drug-dev.com/kane-biotech-announces-agreement-to-acquire-fb-dermatology/ 2024-11-12T18:45:17+00:00 https://drug-dev.com/car-t-cell-therapies-to-pave-way-for-drug-free-remission-in-lupus-care/ 2024-11-13T14:32:57+00:00 https://drug-dev.com/entero-therapeutics-announces-proposed-reverse-merger-with-journey-therapeutics/ 2024-11-13T14:39:07+00:00 https://drug-dev.com/nippon-shinyaku-atsena-therapeutics-enter-exclusive-strategic-collaboration/ 2024-11-13T14:42:38+00:00 https://drug-dev.com/biontech-to-acquire-biotheus-to-boost-oncology-strategy/ 2024-11-13T14:45:20+00:00 https://drug-dev.com/microbiotica-announces-first-patient-dosed-in-its-phase-1b-trial-of-a-precision-microbiome-medicine-in-ulcerative-colitis-patients/ 2024-11-13T14:48:26+00:00 https://drug-dev.com/nxera-pharmas-partner-centessa-initiates-phase-2-trial-of-a-novel-orexin-receptor-2-agonist/ 2024-11-13T14:52:15+00:00 https://drug-dev.com/ac-immune-reports-positive-interim-results-from-phase-2-trial-of-active-immunotherapy-in-early-parkinsons-disease/ 2024-11-14T14:43:59+00:00 https://drug-dev.com/khondrion-receives-fda-clearance-of-inda-for-pivotal-phase-3-trial-of-sonlicromanol-for-treatment-of-primary-mitochondrial-disease/ 2024-11-14T14:47:07+00:00 https://drug-dev.com/aravax-establishes-pharmaceutical-development-base-on-the-oxford-science-park-with-a-focus-on-developing-manufacturing-capabilities-in-the-uk/ 2024-11-14T14:52:57+00:00 https://drug-dev.com/ptc-therapeutics-announces-fda-approval-of-aadc-deficiency-gene-therapy/ 2024-11-14T14:57:02+00:00 https://drug-dev.com/nurexone-biologic-secures-ema-orphan-status-for-exopten-in-spinal-cord-injury/ 2024-11-14T15:01:03+00:00 https://drug-dev.com/alveogene-receives-rare-pediatric-disease-designation-novel-inhaled-gene-therapy-for-lethal-neonatal-surfactant-protein-b-deficiency/ 2024-11-15T14:26:41+00:00 https://drug-dev.com/quotient-sciences-announces-installation-of-worlds-first-gmp-biofoundry-in-a-box-from-centillion-technology/ 2024-11-15T15:15:26+00:00 https://drug-dev.com/bluejay-therapeutics-reports-best-in-class-monoclonal-antibody-achieved-100-virologic-response-up-to-78-combined-virologic-response-alt-normalization-as-monotherapy-in-participants-with-chronic-h/ 2024-11-15T16:04:49+00:00 https://drug-dev.com/enterobiotix-completes-phase-2-study-recruitment-of-ebx-102-02-ibs/ 2024-11-18T14:36:42+00:00 https://drug-dev.com/mbx-biosciences-announces-last-subject-last-visit-in-phase-1-trial-of-mbx-1416-for-the-treatment-of-post-bariatric-hypoglycemia/ 2024-11-18T14:39:49+00:00 https://drug-dev.com/trogenix-unveils-revolutionary-platform-to-transform-cancer-treatment-through-precision-viral-immunotherapy/ 2024-11-18T14:43:19+00:00 https://drug-dev.com/hcw-biologics-wy-biotech-announce-license-agreement-for-immunotherapeutic-product-candidate/ 2024-11-18T14:47:09+00:00 https://drug-dev.com/geovax-announces-positive-interim-data-review-for-phase-2-clinical-trial-of-covid-19-vaccine-booster-in-patients-with-chronic-lymphocytic-leukemia/ 2024-11-19T14:07:02+00:00 https://drug-dev.com/steritas-announces-collaboration-with-argenx-to-advance-evidence-for-novel-steroid-sparing-therapeutics/ 2024-11-19T14:11:23+00:00 https://drug-dev.com/gattefosse-announces-inauguration-of-its-new-premises-technical-center-of-excellence-in-mumbai/ 2024-11-19T14:19:30+00:00 https://drug-dev.com/wp-content/uploads/2024/11/Gattefosse_India_Inauguration-2-scaled.jpg https://drug-dev.com/wp-content/uploads/2024/11/Untitled-1-300x300-2.png https://drug-dev.com/wp-content/uploads/2024/11/Gattefosse_India_Inauguration-3-scaled.jpg https://drug-dev.com/wp-content/uploads/2024/11/Gattefosse_India_Inauguration-1-scaled.jpg https://drug-dev.com/biolojic-design-joins-johnson-johnson-innovation-jlabs/ 2024-11-19T14:27:04+00:00 https://drug-dev.com/ardenas-new-state-of-the-art-nanomedicine-facility-secures-full-gmp-approval-for-manufacturing/ 2024-11-19T14:30:27+00:00 https://drug-dev.com/theolytics-doses-first-patient-in-phase-1-2a-trial-of-theo-260-in-ovarian-cancer/ 2024-11-19T14:33:56+00:00 https://drug-dev.com/pci-pharma-services-chirhoclin-partner-to-prevent-shortage-of-critical-orphan-pancreatic-drug/ 2024-11-19T15:01:11+00:00 https://drug-dev.com/wp-content/uploads/2024/11/ChiRhoStim-Human-Secretin-Vial-1.jpg https://drug-dev.com/genezen-appoints-new-chief-operations-officer/ 2024-11-19T19:06:33+00:00 https://drug-dev.com/immunesensor-therapeutics-receives-orphan-drug-and-rare-pediatric-disease-designations-for-aicardi-goutieres-syndrome-treatment/ 2024-11-20T14:21:08+00:00 https://drug-dev.com/voyager-selects-tau-silencing-gene-therapy-development-candidate-for-alzheimers-disease/ 2024-11-20T14:24:30+00:00 https://drug-dev.com/verge-genomics-announces-milestones-in-collaboration-with-lilly-to-discover-develop-novel-treatments-for-als/ 2024-11-20T14:28:48+00:00 https://drug-dev.com/lonza-announces-first-gmp-batch-completion-at-next-generation-mammalian-manufacturing-facility-in-portsmouth-us/ 2024-11-20T15:05:38+00:00 https://drug-dev.com/abzena-expands-analytical-capabilities-to-include-gmp-cell-based-potency-testing-across-us-uk-sites/ 2024-11-20T18:02:30+00:00 https://drug-dev.com/eradivirs-therapeutic-proven-to-reduce-advanced-stage-influenza-viral-loads-faster-more-thoroughly-in-preclinical-studies-than-current-therapies/ 2024-11-21T14:35:42+00:00 https://drug-dev.com/gri-bio-showcases-gri-0621s-potential-to-reduce-inflammation-type-1-cytokines-reduce-hepatic-fibrosis-in-idiopathic-pulmonary-fibrosis/ 2024-11-21T14:40:45+00:00 https://drug-dev.com/vetter-strengthens-senior-management-team-for-further-sustainable-growth/ 2024-11-21T14:43:00+00:00 https://drug-dev.com/dyadic-receives-3-million-grant-to-develop-cost-effective-monoclonal-antibodies-for-rsv-malaria-using-c1-platform-technology/ 2024-11-21T14:45:28+00:00 https://drug-dev.com/briacell-announces-first-patient-dosed-with-bria-ots-in-metastatic-breast-cancer-study/ 2024-11-21T14:50:50+00:00 https://drug-dev.com/umdf-khondrion-announce-the-mito-funds-investment-in-khondrion-to-support-development-of-one-of-the-most-advanced-drug-candidates-for-primary-mitochondrial-disease/ 2024-11-21T14:53:38+00:00 https://drug-dev.com/lipella-pharmaceuticals-announces-completion-of-first-cohort-in-phase-2a-trial-of-lp-310-for-oral-lichen-planus-advancing-to-next-dose-group/ 2024-11-21T15:02:12+00:00 https://drug-dev.com/bormioli-pharma-invents-the-open-collaborative-innovation-platform-for-the-pharmaceutical-packaging-of-the-future/ 2024-11-22T14:54:58+00:00 https://drug-dev.com/oncoverity-secures-extended-series-a-to-advance-cusatuzumab-in-newly-diagnosed-aml/ 2024-11-22T15:00:07+00:00 https://drug-dev.com/tenaya-therapeutics-doses-first-patient-in-phase-1b-clinical-trial-for-the-treatment-of-pkp2-associated-arrhythmogenic-right-ventricular-cardiomyopathy/ 2024-11-25T13:39:14+00:00 https://drug-dev.com/imunon-announces-results-from-its-end-of-phase-2-meeting-with-the-fda-for-its-lead-imnn-001-clinical-program-in-advanced-ovarian-cancer/ 2024-11-25T13:43:00+00:00 https://drug-dev.com/kanglin-biotechnology-announces-20-million-financing-to-advance-the-development-of-gene-therapies/ 2024-11-25T13:45:21+00:00 https://drug-dev.com/adragos-pharma-acquires-leading-swiss-sterile-fill-finish-expert/ 2024-11-25T13:53:32+00:00 https://drug-dev.com/gelteq-announces-400000-units-enter-production-in-november-2024/ 2024-11-26T13:56:56+00:00 https://drug-dev.com/acg-launches-innovative-tablet-feeder/ 2024-11-26T14:02:02+00:00 https://drug-dev.com/shuttle-pharma-expands-patient-enrollment-for-phase-2-trial-of-ropidoxuridine-for-treatment-of-patients-with-glioblastoma/ 2024-11-26T14:05:24+00:00 https://drug-dev.com/renexxion-ireland-announces-issuance-of-fifth-new-us-patent-covering-novel-crystal-isoform-of-naronapride/ 2024-11-26T14:09:20+00:00 https://drug-dev.com/otsuka-submits-nda-for-bempedoic-acid-in-the-treatment-of-hypercholesterolemia/ 2024-11-26T14:13:05+00:00 https://drug-dev.com/anavex-life-sciences-announces-submission-of-blarcamesine-maa-for-treatment-of-alzheimers-disease-to-ema/ 2024-11-26T14:16:32+00:00 https://drug-dev.com/hovione-expands-global-spray-drying-capacity-with-significant-investment-in-the-us-ireland/ 2024-11-26T14:20:51+00:00 https://drug-dev.com/greenwich-lifesciences-partners-with-gim-in-italy/ 2024-11-26T14:26:04+00:00 https://drug-dev.com/anocca-announces-submission-of-clinical-trial-application-for-multi-asset-trial-vidar-1-in-advanced-pancreatic-cancer/ 2024-11-26T14:31:34+00:00 https://drug-dev.com/adragos-pharma-completes-expansion-with-new-ampoule-fill-finish-line-in-livron/ 2024-11-26T16:50:12+00:00 https://drug-dev.com/nutriband-receives-patent-notice-of-publication-for-its-abuse-deterrent-transdermal-technology/ 2024-11-27T13:56:49+00:00 https://drug-dev.com/marinomed-biotech-ag-signs-agreement-for-sale-of-carragelose-business-to-unither-pharmaceuticals/ 2024-11-27T14:02:29+00:00 https://drug-dev.com/lin-bioscience-receives-fda-fast-track-designation-for-lbs-007/ 2024-11-27T14:05:55+00:00 https://drug-dev.com/sana-biotechnology-announces-fast-track-designation-for-sc291-in-relapsed-refractory-systemic-lupus-erythematosus/ 2024-12-02T15:49:15+00:00 https://drug-dev.com/rigel-announces-r289-granted-fast-track-designation-by-the-fda-for-lower-risk-mds/ 2024-12-02T15:52:34+00:00 https://drug-dev.com/xoma-royalty-acquires-pulmokine-for-20-million-adding-the-royalty-milestone-interest-in-seralutinib-a-phase-3-asset-to-its-portfolio/ 2024-12-02T15:59:24+00:00 https://drug-dev.com/ocular-therapeutix-announces-more-than-300-subjects-randomized-in-sol-1/ 2024-12-02T16:02:10+00:00 https://drug-dev.com/ptc-therapeutics-enters-global-license-collaboration-agreement-with-novartis/ 2024-12-02T16:05:08+00:00 https://drug-dev.com/olema-oncology-announces-new-clinical-trial-collaboration-supply-agreement/ 2024-12-02T16:13:06+00:00 https://drug-dev.com/novelmed-receives-fda-ind-approval-for-the-first-anti-bb-alternative-pathway-blocker-for-treating-primary-immunoglobulin-a-nephropathy-igan-a-renal-disordernovelmed-receives-fda-ind-approval-for-th/ 2024-12-02T17:34:03+00:00 https://drug-dev.com/veranova-recognized-as-one-of-socmas-25-companies-for-industry-leading-safety-programs/ 2024-12-03T14:18:56+00:00 https://drug-dev.com/lonza-launches-tailored-offering-for-smart-capsules-companies-developing-oral-delivery-solutions-for-biologic-drugs/ 2024-12-03T14:22:55+00:00 https://drug-dev.com/recursion-announces-first-patient-dosed-in-phase-1-2-clinical-study-of-a-potential-first-in-class-rbm39-degrader-for-biomarker-enriched-solid-tumors-lymphoma/ 2024-12-03T14:26:15+00:00 https://drug-dev.com/kairos-pharma-adds-city-of-hope-cancer-center-for-phase-2-clinical-trial/ 2024-12-03T14:27:58+00:00 https://drug-dev.com/palisade-bio-announces-preliminary-data-from-phase-1-clinical-study-for-the-treatment-of-moderate-to-severe-ulcerative-colitis-appears-to-be-safe-well-tolerated/ 2024-12-03T14:30:41+00:00 https://drug-dev.com/coherus-announces-agreement-to-divest-udenyca-franchise-for-up-to-558-million-to-intas-pharmaceuticals-ltd/ 2024-12-03T14:35:44+00:00 https://drug-dev.com/roivant-announces-topline-results-from-phase-2-resolve-lung-study-of-namilumab-in-chronic-active-pulmonary-sarcoidosis/ 2024-12-03T14:37:56+00:00 https://drug-dev.com/medigene-receives-milestone-payment-from-regeneron-pharmaceuticals/ 2024-12-03T14:39:41+00:00 https://drug-dev.com/sgs-laboratory-in-ireland-gains-platinum-my-green-lab-certification/ 2024-12-03T14:41:53+00:00 https://drug-dev.com/amarna-therapeutics-partners-with-northx-biologics-to-advance-gene-therapy-development/ 2024-12-03T21:32:02+00:00 https://drug-dev.com/8-years-survival-with-complete-cure-for-a-patient-with-advanced-liver-cancer-being-treated-with-namodenoson-drug/ 2024-12-04T14:37:18+00:00 https://drug-dev.com/tiziana-life-sciences-expands-phase-2-clinical-trial-for-non-active-secondary-progressive-multiple-sclerosis-to-additional-prestigious-us-medical-centers/ 2024-12-04T14:39:44+00:00 https://drug-dev.com/samabriva-accelerates-its-growth-with-new-state-of-the-art-biomanufacturing-facility/ 2024-12-04T14:43:44+00:00 https://drug-dev.com/denali-therapeutics-announces-first-participant-dosed-in-phase-2a-study-of-lrrk2-inhibitor-biib122-in-lrrk2-associated-parkinsons-disease/ 2024-12-05T14:33:14+00:00 https://drug-dev.com/groundbreaking-cretostimogene-grenadenorepvec-monotherapy-data-demonstrates-sustained-durable-complete-responses-in-high-risk-bcg-unresponsive-non-muscle-invasive-bladder-cancer/ 2024-12-05T14:35:45+00:00 https://drug-dev.com/tilt-biotherapeutics-provides-update-on-international-clinical-trial-progress-with-intravenous-delivery-regimen-for-cancer-immunotherapies/ 2024-12-05T14:38:55+00:00 https://drug-dev.com/worlds-first-zero-off-target-base-edited-nk-cell-therapy-receives-ind-approval-in-both-china-us/ 2024-12-05T14:41:33+00:00 https://drug-dev.com/exclusive-unisafe-distribution-agreement-between-owen-mumford-nipro-exceeds-expectations-in-japan-with-new-biosimilar-launch/ 2024-12-06T13:52:55+00:00 https://drug-dev.com/cero-therapeutics-appoints-chris-ehrlich-ceo/ 2024-12-06T14:05:11+00:00 https://drug-dev.com/mestag-therapeutics-announces-licensing-of-novel-inflammatory-disease-target-from-its-raft-platform/ 2024-12-09T13:46:09+00:00 https://drug-dev.com/sonnet-biotherapeutics-announces-topline-safety-data-following-successful-completion-of-son-1010-monotherapy-dose-escalation-in-phase-1-sb101-trial/ 2024-12-09T13:49:07+00:00 https://drug-dev.com/medigene-ag-announces-kras-g12v-as-first-target-for-tcr-guided-t-cell-engagers/ 2024-12-09T13:54:06+00:00 https://drug-dev.com/bionical-emas-sells-emas-pharma-to-kester-capital-following-strategic-review/ 2024-12-09T13:57:08+00:00 https://drug-dev.com/nurexone-announces-promising-preclinical-results-in-restoring-vision-after-optic-nerve-damage/ 2024-12-09T14:04:10+00:00 https://drug-dev.com/wp-content/uploads/2024/12/1.jpg https://drug-dev.com/imunon-announces-continued-strong-improvement-in-overall-survival-data-from-randomized-phase-2-ovation-2-study-of-imnn-001/ 2024-12-10T13:53:43+00:00 https://drug-dev.com/scienture-announces-issuance-of-new-patent-covering-its-first-product-losartan-potassium-oral-suspension-through-2041/ 2024-12-10T13:57:14+00:00 https://drug-dev.com/immutep-announces-initiation-of-phase-3-trial-in-first-line-non-small-cell-lung-cancer/ 2024-12-10T13:58:59+00:00 https://drug-dev.com/eikonizo-therapeutics-announces-investment-by-novo-nordisk-advancing-lead-candidate-toward-clinical-development/ 2024-12-10T14:00:58+00:00 https://drug-dev.com/zealand-pharma-announces-first-participant-enrolled-in-phase-2b-trial-of-petrelintide-in-people-with-overweight-or-obesity/ 2024-12-10T14:02:58+00:00 https://drug-dev.com/uniqure-announces-alignment-with-fda-on-key-elements-of-accelerated-approval-pathway-for-amt-130-in-huntingtons-disease/ 2024-12-10T14:05:09+00:00 https://drug-dev.com/ascendia-pharmaceutical-solutions-launched-to-meet-drug-development-manufacturing-needs/ 2024-12-10T14:08:58+00:00 https://drug-dev.com/arvinas-pfizer-announce-initial-phase-1b-data-from-the-tactive-u-sub-study-of-vepdegestrant-in-combination-with-abemaciclib/ 2024-12-10T14:11:41+00:00 https://drug-dev.com/first-fda-approved-treatment-for-severe-frostbite-now-commercially-available-in-the-us/ 2024-12-10T16:14:18+00:00 https://drug-dev.com/digitialization-platform-breaking-down-communication-barriers-in-pharma-manufacturing/ 2024-12-10T19:16:31+00:00 https://drug-dev.com/wp-content/uploads/2024/12/1-1.jpg https://drug-dev.com/wp-content/uploads/2024/12/2.jpg https://drug-dev.com/executve-interview-aptar-advancing-patient-centric-drug-delivery-digital-health-solutions/ 2024-12-10T19:20:07+00:00 https://drug-dev.com/wp-content/uploads/2024/12/LogoAptarPharma_A1-768x274-1.jpg https://drug-dev.com/wp-content/uploads/2024/12/0.jpg https://drug-dev.com/modified-release-getting-the-right-formula-using-modified-release-formulations-to-address-complex-challenges-in-drug-development/ 2024-12-10T19:30:31+00:00 https://drug-dev.com/wp-content/uploads/2024/12/T1.jpg https://drug-dev.com/drug-development-targeting-the-cd40l-pathway-to-improve-immunosuppression-therapy-help-organ-transplants-last-longer/ 2024-12-10T19:46:12+00:00 https://drug-dev.com/wp-content/uploads/2024/12/F1.jpg https://drug-dev.com/wp-content/uploads/2024/12/F2.jpg https://drug-dev.com/wp-content/uploads/2024/12/F3.jpg https://drug-dev.com/formulation-forum-nanoparticle-technology-for-nose-to-brain-drug-delivery/ 2024-12-10T20:22:39+00:00 https://drug-dev.com/wp-content/uploads/2024/12/F1-1.jpg https://drug-dev.com/wp-content/uploads/2024/12/T1-1.jpg https://drug-dev.com/wp-content/uploads/2024/12/T2.jpg https://drug-dev.com/wp-content/uploads/2024/12/T3.jpg https://drug-dev.com/wp-content/uploads/2024/12/F2-1.jpg https://drug-dev.com/enlivex-receives-regulatory-authorization-for-the-initiation-of-a-phase-1-trial-evaluating-allocetra-in-patients-with-tmj-osteoarthritis/ 2024-12-11T13:54:04+00:00 https://drug-dev.com/hepion-pharmaceuticals-announces-termination-of-merger-agreement/ 2024-12-11T13:56:38+00:00 https://drug-dev.com/briacell-presents-unprecedented-overall-survival-data-in-metastatic-breast-cancer/ 2024-12-11T14:01:02+00:00 https://drug-dev.com/prelude-therapeutics-presents-preliminary-results-of-phase-1-dose-escalation-study-of-prt2527-as-monotherapy-and-in-combination-with-zanubrutinib-in-patients-with-relapsed-refractory-lymphoid-malignan/ 2024-12-11T14:04:17+00:00 https://drug-dev.com/proqr-therapeutics-announces-8-1-million-in-new-funding-from-rett-syndrome-research-trust-to-expand-rna-editing-collaboration/ 2024-12-11T14:07:36+00:00 https://drug-dev.com/eortc-immunocore-announce-enrolment-of-first-patient-onto-the-only-active-phase-3-adjuvant-trial-in-uveal-melanoma/ 2024-12-11T14:10:56+00:00 https://drug-dev.com/candel-therapeutics-announces-can-2409-achieved-primary-endpoint-in-phase-3-prostate-cancer-trial/ 2024-12-11T14:14:38+00:00 https://drug-dev.com/monte-rosa-therapeutics-announces-closing-of-global-license-agreement-with-novartis/ 2024-12-11T14:17:18+00:00 https://drug-dev.com/etherna-announces-discovery-of-novel-mrna-immunotherapeutic-delivered-via-lipid-nanoparticles-that-has-demonstrated-ability-to-eradicate-tumors-in-preclinical-models/ 2024-12-11T14:24:36+00:00 https://drug-dev.com/enterome-presents-encouraging-initial-clinical-data-on-eo4010-in-colorectal-cancer/ 2024-12-11T14:28:28+00:00 https://drug-dev.com/pdcline-pharma-presents-primary-clinical-results-from-phase-i-ii-trial-on-pdclung01-cancer-vaccine/ 2024-12-12T14:34:11+00:00 https://drug-dev.com/immuneering-granted-fda-fast-track-designation-for-imm-1-104-in-advanced-melanoma/ 2024-12-12T14:36:33+00:00 https://drug-dev.com/conduit-pharmaceuticals-to-revolutionize-drug-development-through-agreement-to-use-ai-cybernetics/ 2024-12-12T14:39:40+00:00 https://drug-dev.com/velalabs-announces-strategic-partnership-to-support-biological-drugs-development/ 2024-12-12T20:25:52+00:00 https://drug-dev.com/assertio-announces-results-of-rolvedon-injection-same-day-dosing-clinical-study/ 2024-12-13T13:29:59+00:00 https://drug-dev.com/hutchmed-to-receive-milestone-payment-from-takeda/ 2024-12-13T13:37:27+00:00 https://drug-dev.com/atsena-therapeutics-announces-dosing-completed-in-part-a-of-phase-1-2-clinical-trial-evaluating-gene-therapy-to-treat-x-linked-retinoschisis/ 2024-12-16T14:07:39+00:00 https://drug-dev.com/innoviva-specialty-therapeutics-signs-exclusive-distribution-licensing-agreement/ 2024-12-16T14:12:14+00:00 https://drug-dev.com/verge-genomics-announces-new-development-candidate-a-novel-maintenance-therapy-for-long-term-weight-management/ 2024-12-16T14:14:42+00:00 https://drug-dev.com/palvella-therapeutics-announces-closing-of-merger-with-pieris-pharmaceuticals-concurrent-private-placement-of-78-9-million/ 2024-12-16T14:25:44+00:00 https://drug-dev.com/multilayer-plastic-vials-oxycapt-contributing-to-stability-of-cell-gene-therapy-products/ 2024-12-16T15:09:34+00:00 https://drug-dev.com/wp-content/uploads/2024/12/1-2.jpg https://drug-dev.com/wp-content/uploads/2024/12/2-1.jpg https://drug-dev.com/wp-content/uploads/2024/12/3-1.jpg https://drug-dev.com/wp-content/uploads/2024/12/4.jpg https://drug-dev.com/wp-content/uploads/2024/12/5.jpg https://drug-dev.com/immutep-announces-initial-safety-data-from-first-in-human-phase-1-trial-evaluating-imp761/ 2024-12-17T14:06:33+00:00 https://drug-dev.com/rti-surgical-transforms-into-evergen-a-leading-cdmo-in-regenerative-medicine/ 2024-12-17T14:08:59+00:00 https://drug-dev.com/glyconex-announces-first-patient-dosed-in-phase-3-clinical-trial-for-denosumab-biosimilar/ 2024-12-17T14:11:10+00:00 https://drug-dev.com/eton-pharmaceuticals-announces-final-readout-of-pku-golike-clinical-trial/ 2024-12-17T14:15:25+00:00 https://drug-dev.com/silexion-therapeutics-collaborates-with-evonik-on-advanced-sirna-formulation-development/ 2024-12-17T14:17:44+00:00 https://drug-dev.com/eyedna-therapeutics-receives-rare-pediatric-disease-designation-from-fda-for-its-investigational-gene-therapy-for-patients-with-retinal-dystrophy-due-to-pde6b-gene-mutations/ 2024-12-17T14:22:26+00:00 https://drug-dev.com/safi-biotherapeutics-granted-rare-pediatric-disease-designation-orphan-drug-designation/ 2024-12-18T13:55:12+00:00 https://drug-dev.com/channel-therapeutics-announces-positive-efficacy-data-for-a-depot-formulation-of-a-nav1-7-inhibitor-in-a-preclinical-in-vivo-nerve-block-model/ 2024-12-18T14:09:56+00:00 https://drug-dev.com/wp-content/uploads/2024/12/1.png https://drug-dev.com/wp-content/uploads/2024/12/2.png https://drug-dev.com/silo-pharma-initiates-pharmacokinetic-tolerability-study-for-sp-26-targeting-chronic-pain-fibromyalgia/ 2024-12-18T14:14:56+00:00 https://drug-dev.com/polyrizons-moving-forward-with-expected-2025-clinical-trial-entered-manufacturing-agreement-for-its-pl-14-allergy-blocker/ 2024-12-18T14:17:46+00:00 https://drug-dev.com/coherus-to-present-final-phase-2-casdozokitug-combination-data-in-patients-with-metastatic-hepatocellular-carcinoma/ 2024-12-18T14:22:32+00:00 https://drug-dev.com/vandria-announces-first-subjects-dosed-in-first-in-human-phase-1-trial-of-vna-318-brain-penetrant-mitophagy-inducer/ 2024-12-18T14:30:25+00:00 https://drug-dev.com/evoke-pharma-highlights-gimoti-as-a-leading-solution-for-gastroparesis-treatment-as-domperidone-supply-ends/ 2024-12-19T13:45:58+00:00 https://drug-dev.com/abvc-biopharma-seeks-to-revolutionize-mental-health-treatment-with-a-safe-prozac-alternative/ 2024-12-19T13:51:25+00:00 https://drug-dev.com/gelteq-appoints-new-chief-scientific-officer-to-propel-innovative-ingestible-gel-technology/ 2024-12-19T13:53:41+00:00 https://drug-dev.com/imunon-announces-positive-cmc-meeting-with-fda-for-advanced-ovarian-cancer-treatment/ 2024-12-19T13:56:44+00:00 https://drug-dev.com/assembly-biosciences-announces-30-1-million-investment-accelerated-funding-from-gilead/ 2024-12-19T13:58:47+00:00 https://drug-dev.com/shuttle-pharma-enters-sponsored-research-agreement-with-the-university-of-california-san-francisco-to-advance-psma-development-program/ 2024-12-19T14:03:12+00:00 https://drug-dev.com/lonza-capsules-health-ingredients-expands-capsule-manufacturing-capacity-in-india-china/ 2024-12-19T14:25:31+00:00 https://drug-dev.com/scynexis-initiates-d0osing-in-phase-1-trial-of-a-second-generation-fungerp-candidate-for-invasive-fungal-infections/ 2024-12-19T18:57:38+00:00 https://drug-dev.com/apollomics-announces-top-line-results-for-phase-3-trial-of-uproleselan-in-patients-with-relapsed-or-refractory-acute-myeloid-leukemia/ 2024-12-20T13:08:53+00:00 https://drug-dev.com/gri-bio-announces-european-patent-office-issued-a-decision-to-grant-notice-for-patent-covering-gri-0803-its-library-of-500-proprietary-compounds/ 2024-12-23T14:10:40+00:00 https://drug-dev.com/ikena-oncology-inmagene-biopharmaceuticals-announce-agreement-for-merger-private-placement/ 2024-12-23T14:12:47+00:00 https://drug-dev.com/wave-life-sciences-announces-submission-of-first-clinical-trial-application-for-wve-007-sirna-targeting-inhbe-in-obesity/ 2024-12-23T14:14:37+00:00 https://drug-dev.com/corxel-acquires-worldwide-excluding-greater-china-rights-to-an-oral-small-molecule-for-the-treatment-of-obesity-diabetes/ 2024-12-23T14:18:07+00:00 https://drug-dev.com/obi-pharma-enters-collaboration-with-glytech-to-expand-glycobi-enabling-technologies-outreach-in-japan-to-advance-glycan-production/ 2024-12-23T14:22:42+00:00 https://drug-dev.com/recognition-of-the-american-society-of-clinical-oncology-of-the-liver-protective-effect-of-can-fites-anti-cancer-drug-namodenoson/ 2024-12-30T14:21:52+00:00 https://drug-dev.com/tnf-pharmaceuticals-announces-trial-to-explore-effects-of-lead-candidate-in-sarcopenia-frailty-induced-by-glp-1-weight-loss-drugs/ 2024-12-30T14:32:47+00:00 https://drug-dev.com/eton-pharmaceuticals-advances-its-commitment-to-rare-disease-with-acquisition/ 2025-01-03T14:10:34+00:00 https://drug-dev.com/immuno-oncology-cancer-therapeutics-present-strongest-innovation-pipeline-in-next-5-years/ 2025-01-03T14:14:38+00:00 https://drug-dev.com/acelyrin-to-share-new-phase-2-data-phase-3-program-design-for-subcutaneous-lonigutamab/ 2025-01-03T14:23:18+00:00 https://drug-dev.com/atavistik-bio-announces-research-collaboration-with-pfizer/ 2025-01-03T14:24:37+00:00 https://drug-dev.com/gaelic-laboratories-announces-expansion-enabling-access-to-growing-middle-east-market/ 2025-01-06T14:10:48+00:00 https://drug-dev.com/nuvation-bio-receives-approval-from-chinas-national-medical-products-administration-for-taletrectinib-for-patients-with-advanced-ros1-positive-non-small-cell-lung-cancer/ 2025-01-06T14:14:01+00:00 https://drug-dev.com/fortress-biotech-cyprium-therapeutics-announce-fda-acceptance-priority-review-of-nda-for-cutx-101-for-treatment-of-menkes-disease/ 2025-01-06T14:18:20+00:00 https://drug-dev.com/phillips-medisize-expands-its-inhalation-drug-delivery-capabilities/ 2025-01-07T14:28:40+00:00 https://drug-dev.com/quantro-therapeutics-achieves-breakthrough-in-transcriptomic-drug-discovery/ 2025-01-07T14:31:18+00:00 https://drug-dev.com/fda-accepts-final-protocol-for-pivotal-phase-3-alzheimers-disease-study-streamlining-development-pathway/ 2025-01-07T14:33:04+00:00 https://drug-dev.com/restem-receives-fda-fast-track-designation-for-restem-l-for-idiopathic-inflammatory-myopathy/ 2025-01-07T14:35:04+00:00 https://drug-dev.com/mbx-biosciences-announces-positive-phase-1-topline-results-for-post-bariatric-hypoglycemia-treatment/ 2025-01-07T14:37:33+00:00 https://drug-dev.com/next-generation-rna-company-launched-by-argobio-university-of-southern-denmark/ 2025-01-07T14:39:28+00:00 https://drug-dev.com/denali-therapeutics-announces-topline-results-for-regimen-g-evaluating-eif2b-agonist-dnl343-in-the-phase-2-3-healey-als-platform-trial/ 2025-01-07T14:41:23+00:00 https://drug-dev.com/silo-pharma-awarded-patent-for-groundbreaking-ptsd-treatment/ 2025-01-08T13:56:50+00:00 https://drug-dev.com/abzena-strengthens-board-with-appointment-of-biopharma-industry-leader/ 2025-01-08T13:59:26+00:00 https://drug-dev.com/palvella-therapeutics-announces-first-patients-dosed-in-phase-2-trial-of-qtorin-3-9-rapamycin-anhydrous-gel-for-the-treatment-of-cutaneous-venous-malformations/ 2025-01-08T14:02:07+00:00 https://drug-dev.com/aerwave-completes-first-in-human-study-to-advance-disease-modifying-ultrasound-based-therapy-for-copd-asthma/ 2025-01-08T14:03:30+00:00 https://drug-dev.com/araris-biotech-ag-announces-research-collaboration-option-to-license-agreement-with-chugai-pharmaceutical-co/ 2025-01-08T14:05:57+00:00 https://drug-dev.com/lb-pharmaceuticals-announces-positive-topline-results-from-phase-2-trial-of-lb-102-in-schizophrenia/ 2025-01-08T14:08:48+00:00 https://drug-dev.com/moonlake-initiates-three-new-clinical-trials-further-expands-portfolio-of-indications-for-the-nanobody-sonelokimab/ 2025-01-08T14:15:07+00:00 https://drug-dev.com/rheumagen-launches-with-15-million-financing-to-advance-a-new-class-of-hla-gene-editing-therapies-for-major-autoimmune-diseases/ 2025-01-09T14:40:48+00:00 https://drug-dev.com/inmagene-reports-positive-topline-results-of-a-nondepleting-anti-ox40-monoclonal-antibody-with-an-extended-half-life-for-the-treatment-of-atopic-dermatitis/ 2025-01-09T14:42:54+00:00 https://drug-dev.com/rigel-announces-r289-granted-orphan-drug-designation-for-mds/ 2025-01-09T14:48:57+00:00 https://drug-dev.com/boehringer-ingelheim-acquires-fourth-license-for-the-development-of-novel-antibody-based-cancer-treatments-from-oxford-biotherapeutics/ 2025-01-09T14:51:59+00:00 https://drug-dev.com/genenta-strengthens-agreement-with-agc-biologics-to-boost-cell-therapy-manufacturing/ 2025-01-09T14:55:46+00:00 https://drug-dev.com/menarini-group-insilico-medicine-enter-second-exclusive-global-license-agreement/ 2025-01-10T14:09:43+00:00 https://drug-dev.com/windward-bio-launches-with-200-million-financing-to-develop-phase-2-ready-long-acting-anti-tslp-antibody-with-best-in-class-potential-in-asthma-copd/ 2025-01-10T14:13:13+00:00 https://drug-dev.com/bioduro-opens-new-solid-phase-peptide-synthesis-scale-up-facility/ 2025-01-10T14:14:46+00:00 https://drug-dev.com/invivyd-announces-continued-neutralizing-activity-of-pemgarda-against-dominant-sars-cov-2-variant-xec/ 2025-01-10T14:31:19+00:00 https://drug-dev.com/2025-company-profiles-capabilities/ 2025-01-10T14:48:55+00:00 https://drug-dev.com/sling-therapeutics-announces-positive-topline-results-from-phase-2b-3-trial-of-oral-small-molecule-linsitinib-in-patients-with-thyroid-eye-disease/ 2025-01-14T14:01:00+00:00 https://drug-dev.com/kindeva-drug-delivery-emervax-partner-to-bring-game-changing-vaccine-administration-to-patients/ 2025-01-14T14:07:22+00:00 https://drug-dev.com/pheno-therapeutics-granted-clinical-trial-authorization-for-lead-multiple-sclerosis-therapeutic-candidate/ 2025-01-14T14:10:58+00:00 https://drug-dev.com/pulsesight-therapeutics-announces-initiation-of-clinical-plan-of-transferrin-vectorized-therapy-for-dry-amd-geographic-atrophy/ 2025-01-14T14:14:21+00:00 https://drug-dev.com/biomed-x-institute-launches-new-collaboration-with-daiichi-sankyo-in-cancer-therapy/ 2025-01-14T14:19:51+00:00 https://drug-dev.com/micron-biomedical-wins-2-million-barda-competition-for-its-collaboration-with-zipcode-bio-to-develop-mrna-based-broad-protecting-flu-vaccine-without-needles/ 2025-01-14T14:25:08+00:00 https://drug-dev.com/vetter-introduces-the-next-evolution-of-the-v-ovs-syringe-closure-system/ 2025-01-14T14:37:01+00:00 https://drug-dev.com/wp-content/uploads/2025/01/Picture1.jpg https://drug-dev.com/alcami-announces-ceo-transition/ 2025-01-14T14:42:12+00:00 https://drug-dev.com/wp-content/uploads/2025/01/Patrick-Walsh-Headshot-scaled.jpg https://drug-dev.com/iconovo-lonza-to-collaborate-on-the-formulation-development-of-an-intranasal-biologic/ 2025-01-14T14:48:09+00:00 https://drug-dev.com/abzena-strengthens-board-with-appointment-of-biopharma-industry-leader-dr-moncef-slaoui/ 2025-01-14T15:28:46+00:00 https://drug-dev.com/anavex-life-sciences-announces-peer-reviewed-publication-of-oral-blarcamesine-phase-2b-3-data/ 2025-01-15T14:05:51+00:00 https://drug-dev.com/attralus-announces-enrollment-of-first-patient-in-phase-3-trial-for-the-pan-amyloid-diagnostic-124i-evuzamitide-at-01-for-cardiac-amyloidosis/ 2025-01-15T14:08:10+00:00 https://drug-dev.com/lyndra-therapeutics-announces-strategic-clinical-research-commercial-manufacturing-services-collaboration-with-thermo-fisher-scientific/ 2025-01-15T15:39:25+00:00 https://drug-dev.com/kindeva-drug-delivery-awarded-up-to-129-million-to-supply-duodote-autoinjectors-to-the-strategic-national-stockpile/ 2025-01-16T14:39:37+00:00 https://drug-dev.com/nipro-nemera-prove-compatibility-of-unit-dose-microvials-unispray/ 2025-01-16T14:45:21+00:00 https://drug-dev.com/wp-content/uploads/2025/01/Picture2.png https://drug-dev.com/palisade-bio-completes-all-five-sad-cohorts-advances-to-mad-cohorts-of-phase-1a-b-study-of-pali-2108-for-treatment-of-ulcerative-colitis/ 2025-01-16T14:48:04+00:00 https://drug-dev.com/registration-opens-for-interphex-2025-april-1-3-in-nyc/ 2025-01-16T14:50:56+00:00 https://drug-dev.com/recibiopharm-secures-significant-grant-to-advance-rna-manufacturing/ 2025-01-20T14:33:43+00:00 https://drug-dev.com/micron-biomedical-extends-series-a-financing-to-33-million-to-accelerate-commercialization-of-needle-free-therapeutics-vaccines/ 2025-01-20T15:13:15+00:00 https://drug-dev.com/sonnet-biotherapeutics-expands-phase-1-sb101-trial-to-evaluate-combination-of-son-1010-with-trabectedin-in-certain-sarcomas/ 2025-01-21T14:35:33+00:00 https://drug-dev.com/shuttle-pharma-reaches-milestone-in-patient-enrollment-for-phase-2-trial-of-ropidoxuridine-for-treatment-of-patients-with-glioblastoma/ 2025-01-21T14:37:42+00:00 https://drug-dev.com/coya-therapeutics-announces-pipeline-expansion-coya-303-coya-301-in-combination-with-glp-1-receptor-agonist-for-the-treatment-of-inflammatory-diseases/ 2025-01-21T14:39:48+00:00 https://drug-dev.com/bluejay-therapeutics-receives-fda-breakthrough-therapy-designation-for-brelovitug-for-the-treatment-of-chronic-hepatitis-delta/ 2025-01-21T14:41:53+00:00 https://drug-dev.com/altamira-therapeutics-announces-collaboration-on-radiopharmaceutical-targeting-strategies/ 2025-01-22T14:17:09+00:00 https://drug-dev.com/artax-biopharma-achieves-clinical-validation-of-first-in-class-oral-nck-modulator-for-autoimmune-disease-in-phase-2a-study/ 2025-01-22T14:19:37+00:00 https://drug-dev.com/silo-pharma-advances-intellectual-property-portfolio-with-provisional-patent-filing-for-ptsd-treatment/ 2025-01-22T14:23:47+00:00 https://drug-dev.com/immvention-therapeutix-enters-strategic-collaboration-with-novo-nordisk-to-develop-oral-therapies/ 2025-01-22T14:26:25+00:00 https://drug-dev.com/arrivent-biopharma-enters-exclusive-license-with-lepu-biopharma-for-an-antibody-drug-conjugate-for-the-treatment-of-gastrointestinal-cancers/ 2025-01-22T14:29:05+00:00 https://drug-dev.com/sanara-medtech-inc-announces-exclusive-license-distribution-agreement-with-minority-investment-in-biomimetic-innovations-ltd/ 2025-01-22T14:36:04+00:00 https://drug-dev.com/lisata-therapeutics-warpnine-announce-encouraging-preliminary-results-from-phase-1b-2a-ilsta-trial/ 2025-01-23T14:35:28+00:00 https://drug-dev.com/incannex-healthcare-announces-positive-topline-results-from-pharmacokinetics-study-of-an-oral-combination-medicine-for-the-treatment-of-obstructive-sleep-apnea/ 2025-01-23T14:40:20+00:00 https://drug-dev.com/attovia-therapeutics-announces-first-participant-dosed-in-first-in-human-phase-1-study-of-atto-1310-its-novel-half-life-extended-anti-il-31-attobody-for-the-treatment-of-chronic-pruritus/ 2025-01-23T14:42:14+00:00 https://drug-dev.com/aliri-launches-qpcr-to-complement-existing-lineup-of-multi-omics-platforms/ 2025-01-23T14:46:57+00:00 https://drug-dev.com/fortress-biotech-announces-first-patient-dosed-in-phase-2-trial-of-triplex-vaccination-in-stem-cell-donors-to-reduce-cmv-events-in-recipients-of-hsct/ 2025-01-27T14:30:17+00:00 https://drug-dev.com/cartesian-therapeutics-announces-fda-special-protocol-assessment-agreement-for-phase-3-aurora-trial-of-descartes-08-in-myasthenia-gravis/ 2025-01-27T14:35:43+00:00 https://drug-dev.com/us-patent-office-granted-can-fite-namodenoson-patent-for-use-as-anti-obesity-drug/ 2025-01-27T14:39:10+00:00 https://drug-dev.com/gt-biopharma-announces-first-patient-dosed-in-phase-1-trial-of-second-generation-trike-for-the-treatment-of-hematologic-malignancies/ 2025-01-27T14:42:26+00:00 https://drug-dev.com/alvotech-teva-announce-filing-acceptance-of-us-biologics-license-applications-for-a-proposed-biosimilar-to-simponi-simponi-aria/ 2025-01-27T14:47:17+00:00 https://drug-dev.com/nemera-awarded-ecovadis-gold-medal-a-recognition-of-its-commitment-to-sustainable-development/ 2025-01-28T14:42:15+00:00 https://drug-dev.com/sonnet-biotherapeutics-further-expands-global-intellectual-property-portfolio-with-issuance-of-patent-for-platform-technology/ 2025-01-28T14:45:49+00:00 https://drug-dev.com/upperton-completes-build-of-new-sterile-manufacturing-facility/ 2025-01-28T14:48:02+00:00 https://drug-dev.com/silexion-therapeutics-reports-strong-tumor-growth-reduction-from-systemic-administration-of-sil-204-in-preclinical-pancreatic-cancer-models/ 2025-01-28T14:51:42+00:00 https://drug-dev.com/march-biosciences-receives-fda-orphan-drug-designation-for-mb-105-a-first-in-class-cd5-car-t-cell-therapy-for-t-cell-lymphoma/ 2025-01-28T14:53:22+00:00 https://drug-dev.com/schrodinger-selects-sapio-sciences-to-enhance-in-silico-drug-discovery-from-plasmid-to-structure/ 2025-01-28T16:43:32+00:00 https://drug-dev.com/ocean-biomedical-advances-malaria-vaccine-research-with-new-nih-funding-expedited-development-pathway/ 2025-01-29T14:34:57+00:00 https://drug-dev.com/northstrive-biosciences-signs-agreement-for-a-potential-breakthrough-obesity-therapy-targeting-fat-loss-muscle-preservation-in-combination-with-glp-1/ 2025-01-30T14:53:10+00:00 https://drug-dev.com/rentschler-biopharma-announces-strategic-realignment-of-its-global-business-operations/ 2025-01-30T14:55:24+00:00 https://drug-dev.com/jupiter-neurosciences-partners-with-zina-biopharmaceuticals-to-advance-phase-2a-parkinsons-trial/ 2025-01-30T14:58:23+00:00 https://drug-dev.com/sgs-introduces-first-commercial-cell-sorting-service-for-the-biopharmaceutical-industry/ 2025-01-30T15:11:19+00:00 https://drug-dev.com/nuvation-bio-announces-expanded-access-program-in-the-us-for-taletrectinib-in-advanced-ros1-positive-non-small-cell-lung-cancer/ 2025-02-03T15:29:48+00:00 https://drug-dev.com/jupiter-neurosciences-announces-manufacturing-agreement-with-catalent/ 2025-02-03T15:36:59+00:00 https://drug-dev.com/salarius-pharmaceuticals-announces-patient-enrollment-to-resume-in-investigator-initiated-phase-1-2-clinical-trial-using-seclidemstat-with-azacitidine-to-treat-hematologic-cancers/ 2025-02-03T15:40:18+00:00 https://drug-dev.com/hcw-biologics-granted-fda-clearance-to-evaluate-one-of-its-lead-product-candidates-in-a-first-in-human-phase-1-clinical-trial/ 2025-02-03T15:52:33+00:00 https://drug-dev.com/purple-biotech-announces-research-collaboration-with-the-icahn-school-of-medicine-at-mount-sinai/ 2025-02-03T15:57:09+00:00 https://drug-dev.com/biontech-completes-acquisition-of-biotheus/ 2025-02-03T16:02:12+00:00 https://drug-dev.com/northstrive-biosciences-reports-positive-updates-for-obesity-drug-candidates/ 2025-02-04T14:36:30+00:00 https://drug-dev.com/ardena-completes-acquisition-of-advanced-drug-product-manufacturing-facility-from-catalent-expands-bioanalytical-services-in-north-america/ 2025-02-04T14:39:09+00:00 https://drug-dev.com/gelteq-launches-sportsgel-brand-signs-distribution-agreement-with-e-commerce-solutions-company/ 2025-02-04T14:41:47+00:00 https://drug-dev.com/quantum-biopharma-announces-the-success-of-unbuzzd-clinical-trial/ 2025-02-04T14:46:06+00:00 https://drug-dev.com/annovis-announces-first-patients-entered-into-pivotal-phase-3-study-of-buntanetap-for-early-alzheimers-disease/ 2025-02-05T14:35:32+00:00 https://drug-dev.com/indaptus-therapeutics-receives-approval-from-health-canada-to-expand-clinical-trial-of-decoy20/ 2025-02-05T14:38:45+00:00 https://drug-dev.com/gradalis-secures-fda-regenerative-medicine-advanced-therapy-designation-for-investigational-personalized-immunotherapy-for-advanced-ovarian-cancer/ 2025-02-05T14:43:22+00:00 https://drug-dev.com/144300-2/ 2025-02-05T15:03:01+00:00 https://drug-dev.com/wp-content/uploads/2024/10/Lonza-Logo-768x139-1.jpg https://drug-dev.com/wp-content/uploads/2024/10/0.jpg https://drug-dev.com/thermo-fisher-scientific-launches-international-corevitas-clinical-registry-in-adolescent-alopecia-areata/ 2025-02-05T15:27:08+00:00 https://drug-dev.com/maze-therapeutics-doses-first-patient-in-phase-2-trial-evaluating-mze829-as-a-potential-treatment-for-apol1-kidney-disease/ 2025-02-07T14:37:14+00:00 https://drug-dev.com/conduit-pharmaceuticals-transitions-to-phase-2-of-sarborg-collaboration-to-support-ai-driven-drug-development/ 2025-02-07T14:40:04+00:00 https://drug-dev.com/alumis-acelyrin-to-merge-creating-a-late-stage-clinical-biopharma-company/ 2025-02-07T14:45:58+00:00 https://drug-dev.com/recipharm-expands-aseptic-filling-capabilities-for-process-development-pilot-scale-clinical-supply/ 2025-02-07T15:15:05+00:00 https://drug-dev.com/biodexa-receives-us-fda-fast-track-designation-for-erapa-in-familial-adenomatous-polyposis/ 2025-02-10T14:51:31+00:00 https://drug-dev.com/safi-biotherapeutics-armi-biofabusa-initiate-collaboration-to-support-large-scale-development-of-mrbcs/ 2025-02-10T14:56:13+00:00 https://drug-dev.com/ocean-biomedical-announces-breakthrough-findings-in-egfr-mutant-lung-cancer-plans-for-fda-alignment-on-next-stage-development/ 2025-02-10T14:59:31+00:00 https://drug-dev.com/focused-ultrasound-overcoming-drug-delivery-challenges/ 2025-02-10T15:49:01+00:00 https://drug-dev.com/wp-content/uploads/2025/02/1.jpg https://drug-dev.com/wp-content/uploads/2025/02/2.jpg https://drug-dev.com/oxygen-scavenging-innovative-oxygen-scavenging-technologies-for-pharmaceutical-packaging-ensuring-drug-integrity-stability/ 2025-02-10T16:14:48+00:00 https://drug-dev.com/wp-content/uploads/2025/02/F1.jpg https://drug-dev.com/wp-content/uploads/2025/02/F23.jpg https://drug-dev.com/wp-content/uploads/2025/02/F4jpg.jpg https://drug-dev.com/cell-separation-technology-breaking-down-barriers-to-unlock-a-new-era-of-cell-therapy/ 2025-02-10T16:17:56+00:00 https://drug-dev.com/wp-content/uploads/2024/11/Yu-Figure-1.png https://drug-dev.com/wp-content/uploads/2024/11/Yu-Figure-2.jpg https://drug-dev.com/new-product-introduction-addressing-the-pitfalls-of-progressing-from-pilot-to-product-through-effective-new-product-introduction/ 2025-02-10T16:32:41+00:00 https://drug-dev.com/outtsourcing-pharma-development-harnessing-cdmos-for-innovation-efficiency/ 2025-02-10T18:07:03+00:00 https://drug-dev.com/wp-content/uploads/2025/02/1-1.jpg https://drug-dev.com/wp-content/uploads/2025/02/2-1.jpg https://drug-dev.com/vaccine-development-enhancing-pandemic-preparedness-with-mosaic-8b-nanoparticles/ 2025-02-10T18:23:32+00:00 https://drug-dev.com/wp-content/uploads/2025/02/1-2.jpg https://drug-dev.com/wp-content/uploads/2025/02/2-2.jpg https://drug-dev.com/executive-interview-lifecore-biomedical-capacity-to-keep-pace-with-biologics-growth/ 2025-02-10T18:30:51+00:00 https://drug-dev.com/wp-content/uploads/2025/02/1-3.jpg https://drug-dev.com/drug-development-what-is-formulation-development-why-is-it-important/ 2025-02-10T18:49:36+00:00 https://drug-dev.com/wp-content/uploads/2025/02/T1.jpg https://drug-dev.com/wp-content/uploads/2025/02/F1-1.jpg https://drug-dev.com/microneedle-manufacturing-the-value-of-a-manufacturing-oriented-microneedle-mindset/ 2025-02-10T19:22:53+00:00 https://drug-dev.com/wp-content/uploads/2025/02/1-4.jpg https://drug-dev.com/wp-content/uploads/2025/02/2-3.jpg https://drug-dev.com/wp-content/uploads/2025/02/3.jpg https://drug-dev.com/wp-content/uploads/2025/02/4.jpg https://drug-dev.com/silo-pharma-announces-positive-initial-pharmacokinetic-safety-tolerability-study-of-sp-26-for-chronic-pain-and-fibromyalgia/ 2025-02-11T14:39:14+00:00 https://drug-dev.com/formulation-forum-nanoparticle-technologies-for-oral-delivery-of-peptides-proteins/ 2025-02-11T15:47:59+00:00 https://drug-dev.com/wp-content/uploads/2025/02/F1-2.jpg https://drug-dev.com/wp-content/uploads/2025/02/T1-1.jpg https://drug-dev.com/wp-content/uploads/2025/02/T2.jpg https://drug-dev.com/wp-content/uploads/2025/02/T3.jpg https://drug-dev.com/leadership-panel-what-will-have-the-most-impact-on-drug-development-in-2025/ 2025-02-11T16:12:45+00:00 https://drug-dev.com/wp-content/uploads/2025/02/Uwe-1.jpg https://drug-dev.com/wp-content/uploads/2025/02/Eric.jpg https://drug-dev.com/wp-content/uploads/2025/02/Tony.jpg https://drug-dev.com/wp-content/uploads/2025/02/Fiona.jpg https://drug-dev.com/wp-content/uploads/2025/02/Melanie.jpg https://drug-dev.com/mediwound-initiates-the-value-global-phase-3-pivotal-trial-of-escharex-for-treatment-of-venous-leg-ulcers/ 2025-02-12T14:30:54+00:00 https://drug-dev.com/mangoceuticals-advances-antiviral-research-on-its-patented-respiratory-illness-prevention-technology/ 2025-02-12T14:36:08+00:00 https://drug-dev.com/abcuro-announces-200-million-financing-to-advance-its-first-in-class-medicine-in-development-for-inclusion-body-myositis/ 2025-02-12T14:38:42+00:00 https://drug-dev.com/bicara-therapeutics-announces-first-patients-enrolled-in-fortifi-hn01-a-pivotal-phase-2-3-clinical-trial-of-ficerafusp-alfa-in-1l-recurrent-metastatic-head-neck-squamous-cell-carcinoma/ 2025-02-12T14:46:10+00:00 https://drug-dev.com/mediwound-ltd-developing-a-new-class-of-biologic-enzymatic-therapeutic-products-to-debride-wounds/ 2025-02-12T20:39:25+00:00 https://drug-dev.com/wp-content/uploads/2024/10/MEDIWOUND.jpg https://drug-dev.com/wp-content/uploads/2024/10/OferGonen-scaled.jpg https://drug-dev.com/executive-interview-resilience-rising-advancing-therapies-that-transform-lives/ 2025-02-12T20:40:44+00:00 https://drug-dev.com/wp-content/uploads/2025/02/JanFeb-HIRES-29.jpg https://drug-dev.com/in8bio-presents-positive-phase-1-data-highlighting-durability-of-remissions-in-high-risk-aml/ 2025-02-14T15:24:25+00:00 https://drug-dev.com/artelo-biosciences-announces-new-data-on-art12-11-tablets-showing-improved-pharmacokinetics-to-epidiolex/ 2025-02-14T15:26:41+00:00 https://drug-dev.com/special-feature-analytical-testing-diverse-demands-therapies-require-diverse-analyses/ 2025-02-14T15:56:18+00:00 https://drug-dev.com/wp-content/uploads/2025/02/Aliri.jpg https://drug-dev.com/wp-content/uploads/2025/02/Inotiv.jpg https://drug-dev.com/wp-content/uploads/2025/02/Eurofins.jpg https://drug-dev.com/wp-content/uploads/2025/02/Lifecore.jpg https://drug-dev.com/wp-content/uploads/2025/02/Millipore.jpg https://drug-dev.com/wp-content/uploads/2025/02/Stevanato.jpg https://drug-dev.com/silo-pharma-expands-intellectual-property-portfolio-with-provisional-patent/ 2025-02-18T14:58:49+00:00 https://drug-dev.com/atrandi-biosciences-raises-25m-series-a-led-by-lux-capital-to-drive-the-future-of-single-cell-multiomics-with-semi-permeable-capsule-technology/ 2025-02-19T14:32:39+00:00 https://drug-dev.com/imunon-announces-translational-data-from-phase-1-2-ovation-2-study-of-imnn-001-in-advanced-ovarian-cancer/ 2025-02-19T14:39:23+00:00 https://drug-dev.com/medigene-ag-expands-patent-portfolio-with-patent-grant-for-its-jovi-technology-in-the-us/ 2025-02-19T14:43:36+00:00 https://drug-dev.com/tiziana-life-sciences-announces-agreement-for-product-development-services-with-renaissance-lakewood/ 2025-02-21T14:20:08+00:00 https://drug-dev.com/phoenix-molecular-designs-dosed-first-patient-in-dauntless-1-a-phase-2-clinical-trial-of-pmd-026-in-combination-with-fulvestrant-for-rsk2-high-breast-cancer/ 2025-02-21T14:34:24+00:00 https://drug-dev.com/neurona-unveils-phase-3-epic-study-for-nrtx-1001-cell-therapy-in-epilepsy/ 2025-02-21T14:42:22+00:00